Concord Biotech Limited reported earnings results for the fourth quarter and full year ended March 31, 2026. For the fourth quarter, the company reported sales was INR 3,260.8 million compared to INR 4,298.84 million a year ago. Revenue was INR 3,414.29 million compared to INR 4,392.68 million a year ago. Net income was INR 887.91 million compared to INR 1,403.87 million a year ago. Basic earnings per share from continuing operations was INR 8.46 compared to INR 13.42 a year ago.
For the full year, sales was INR 10,548.91 million compared to INR 12,000.87 million a year ago. Revenue was INR 11,072.46 million compared to INR 12,445.34 million a year ago. Net income was INR 2,609.06 million compared to INR 3,716.42 million a year ago. Basic earnings per share from continuing operations was INR 24.78 compared to INR 35.52 a year ago.
Concord Biotech Limited is an India-based research and development-driven biopharmaceutical company focused on manufacturing fermentation-based active pharmaceutical ingredients (APIs) and formulations. The Company is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its product portfolio encompasses both biopharmaceutical APIs and formulations across various therapeutic areas, including immunosuppressants, oncology, anti-infectives, nephrology, and critical care. Its API products include Immunosuppressant, Oncology Drugs, Anti-bacterial, and others. Its Immunosuppressant include Tacrolimus, Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, and Voclosporin. Its Oncology Drugs include Temsirolimus, Everolimus, Romidepsin, Mitomycin, Dactinomycin, Midostaurin, and Doxorubicin. Its Anti-bacterial include Mupirocin, Mupirocin Calcium, Teicoplanin, and others.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
